Partners In Practice Articles

Hope for Metastatic Colorectal Cancer Patients

Renuka Iyer, MD, Co-Director, Liver and Pancreas Tumor Program and Section Chief for Gastrointestinal Oncology, describes how research and clinical trials are offering renewed hope to patients with metastatic colorectal cancer.

BRAF and MEK Inhibitors in Melanoma

High constitutive activity of MAPK pathway has been shown in a majority of melanomas. To date, BRAF and MEK have been shown to be clinically relevant components of this pathway with proven efficacy of agents targeted to BRAF and MEK.

BRAF Inhibitors in Lung Cancer

BRAF mutations have been reported in 3% of non-small cell lung cancers (NSCLC), only in adenocarcinoma sub-type of NSCLC. Although uncommon, BRAF mutations represent a valid potential target as multiple RAF kinase inhibitors are available. BRAF V600E mutation is reported in 2% of NSCLC.

BRAF and MEK Inhibitors in Colorectal Cancer

BRAF mutation has been reported in approximately 10–15% of colorectal cancers. Data also supports presence of BRAF mutations as a poor prognostic factor, as well as a potential biomarker of lack of response to EGFR directed therapy in KRAS wild type colorectal cancer.